Proteintech and HebeCell announced a collaboration to develop a proprietary nanobody based chimeric antigen receptor (nCAR) technology for development and the commercialization of induced pluripotent stem cell-derived natural killer cells (iPSC-nCAR-NK), a promising cellular immunotherapy for the treatment of cancer and other diseases.

Proteintech's recent acquisition of nano-body manufacturer ChromoTek made the company a major player in the nano-body industry. ChromoTek's high-performance single-chain camelid recombinant reagents, also known as nano-bodies, are sparking groundbreaking scientific discoveries.

HebeCell has unmatched expertise and an intellectual property portfolio in induced pluripotent stem cells (iPSCs) and related lineage-specific differentiation, especially in relation to natural killer (NK) cells. NK cells are known to kill virus-infected cells, but they also play an essential role in detecting and controlling early signs of cancer.

“The collaboration with Proteintech will give both companies a competitive advantage,” said Dr. Allen Feng, founder and chief scientific officer of HebeCell, who added: “The union of our skills and technologies creates a unique and special collaboration that will improve the therapies and care provided to cancer patients. "

Dr. Jason Li, CEO of Proteintech, added: “I have known Dr. John Lu, founder and CEO of HebeCell, for many years and I am delighted to have the opportunity to work together on this important project. With HebeCell's patented NK cells and Proteintech's nano-bodies, the two companies can transform the future of cancer therapies.

About Proteintech Group Inc.

Proteintech is a prestigious producer of antibodies, proteins and immunoassays for all research areas. Proteintech has the largest portfolio of patented self-produced antibodies ever covering two thirds of the human proteome. Proteintech produces cytokines, growth factors and other proteins expressed by humans, bioactive and compliant with current Good Manufacturing Practice (cGMP). Thanks to the acquisition of the manufacturer ChromoTek, Proteintech now supplies innovative reagents based on camelid antibodies called nano-bodies. Proteintech factories have ISO13485 and ISO9001-2015 certifications.

About HebeCell Corporation

Founded in 2016, HebeCell specializes in the branch of immunotherapies through the development of "ready to use" natural killer cells that express the chimeric antigen receptor (CAR-NK) and which are based on human induced pluripotent stem (iPSC) cells and other cell-based therapies of the immune system for the treatment of haematological malignancies and solid tumors, as well as autoimmune and infectious diseases. HebeCell possesses expertise and capabilities in lineage-specific iPSC differentiation and state-of-the-art cell manufacturing facilities compliant with current good manufacturing practice. Its patented powerless 3D platform, the first of its kind, for the production of iPSC-CAR-NK cells was specially developed for industrial-scale single-use bioreactors, which allows the rapid implementation of ready-to-use CAR-NK cell products for all patients. Technology incorporated into HebeCell's platform will accelerate the application of iPSC cells as a reliable source of immune system cells for the next generation of immunotherapies and revolutionize the branch of CAR-NK cell-based therapies by offering cost-effective allogeneic therapeutic products all over the world.

The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the reader's convenience and must refer to the original text, which is the only legally valid text.

Contacts
Thompson + Conard Communications
Jane Thompson
jane@thompsonconard.com
1-415-710-1675

 

Source: businesswire.com

Report Abuse